OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Mahtani on the Expansion of Targeted Therapies in HER2+ Breast Cancer

March 22nd 2024

Reshma L. Mahtani, DO, discusses how the expansion of HER2-targeted agents has impacted the management of HER2-positive breast cancer.

Dr Borgen on the Debate Over Routine MRI Testing in Early-Stage Breast Cancer

March 22nd 2024

Patrick I. Borgen, MD, discusses the ongoing debate of routine MRI testing in early-stage breast cancer.

Dr Konecny on the FDA Approval of Mirvetuximab Soravtansine for FRα+ Platinum-Resistant Ovarian Cancer

March 22nd 2024

Gottfried E. Konecny, MD, discusses the FDA approval of mirvetuximab soravtansine for patients with FRα-positive, platinum-resistant ovarian cancer.

Dr D’Amico on Advancements in High-Risk Prostate Cancer Diagnosis and Management

March 22nd 2024

Anthony V. D'Amico, MD, PhD, on the advancements in high-risk prostate cancer diagnosis and management

Dr Kuerer on Advancements in Neoadjuvant Systemic Therapies in Breast Cancer

March 22nd 2024

Henry Kuerer, MD, PhD, FACS, CMQ, on significant advancements in neoadjuvant systemic therapies in breast cancer treatment

Dr Lee on Head and Neck Cancer Updates from the 2024 ACRO Summit

March 21st 2024

Anna Lee, MD, MPH, discusses key takeaways from a presentation on managing head and neck cancers that was given at the 2024 ACRO Summit.

Dr Masters on the 2024 ACRO Summit

March 21st 2024

Adrianna Masters, MD, PhD, discusses pivotal events from the 2024 ACRO Summit, emphasizing the importance of mentorship in radiation oncology.

Dr Hacker on the Proportion of HER2-Expressing Tumors in Endometrial Cancer

March 21st 2024

Kari Hacker, MD, PhD, discusses the proportion of HER2-expressing endometrial cancers eligible for HER2-targeted antibody-drug conjugate treatment.

Dr Tanyi on the Use of Pafolacianine for Intraoperative Molecular Imaging in FRα+ Ovarian Cancer

March 21st 2024

Janos L. Tanyi, MD, PhD, discusses the use of pafolacianine sodium injections during cytoreductive surgery in FRα–positive ovarian cancer.

Dr Jabbour on the Significance of the FDA Approval of Ponatinib Plus Chemo for PH+ ALL

March 20th 2024

Elias Jabbour, MD, discusses the FDA approval of ponatinib plus chemotherapy for Philadelphia chromosome–positive acute lymphoblastic leukemia.

Dr Hernandez-Ilizaliturri on the Potential Advantages of Iopofosine I 131 in Waldenström Macroglobulinemia

March 20th 2024

Francisco Hernandez-Ilizaliturri, MD, discusses the unique potential advantages of the radiotherapeutic iopofosine I 131 in Waldenström macroglobulinemia.

Dr Taplin on Health Care Inequities in Prostate Cancer Treatment

March 20th 2024

Mary-Ellen Taplin, MD, discusses strategies to mitigate health care inequities in prostate cancer.

Dr Antonarakis on Early Intervention With PARP Inhibitors in mHSPC

March 20th 2024

Emmanuel Antonarakis, MD, discusses the significance of TALPRO-3, EVOPAR, and AMPLITUDE trials on the metastatic prostate cancer treatment paradigm.

Dr Mahtani on Unique Challenges Women in Oncology Experience During Career Transitions

March 19th 2024

Reshma L. Mahtani, DO, discusses unique challenges women may face when transitioning between different career roles within oncology.

Dr Richter on Ongoing Research With Bispecific Antibodies in R/R Multiple Myeloma

March 19th 2024

Joshua Richter, MD, discusses ongoing or upcoming research with bispecific antibodies in relapsed/refractory multiple myeloma.

Dr Marth on Frontline Lenvatinib Plus Pembrolizumab in Endometrial Cancer

March 19th 2024

Christian Marth, MD, PhD, discusses the LEAP-001 trial of lenvatinib plus pembrolizumab vs chemotherapy in advanced or recurrent endometrial cancer.

Dr Mirza on the Findings From Part 2 of the RUBY Trial in Endometrial Cancer

March 19th 2024

Mansoor Raza Mirza, MD, discusses findings from part 2 of the ENGOT-EN6-NSGO/GOG-3031/RUBY trial in primary advanced or recurrent endometrial cancer.

Dr Hayek on Laparoscopic vs Open Surgery in Advanced Ovarian Cancer

March 17th 2024

Judy Hayek, MD, discusses outcomes with minimally invasive vs open interval complete gross resection in patients with advanced ovarian cancer.

Dr Randall on PROs With Pembrolizumab Plus Chemoradiotherapy in Cervical Cancer

March 17th 2024

Leslie M. Randall, MD, MAS, discusses patient-reported outcomes from the ENGOT-cx11/GOG 3047/KEYNOTE-A18 trial in locally advanced cervical cancer.

Dr Nasioudis on the Use of SLNB in Metastatic Vulvar Squamous Cell Carcinoma

March 16th 2024

Dimitrios Nasioudis, MD, discusses outcomes of patients with metastatic vulvar squamous cell carcinoma who underwent sentinel lymph node biopsy.